MDNews - Mid Penn

Insights 2020

Issue link: https://viewer.e-digitaledition.com/i/1255745

Contents of this Issue

Navigation

Page 7 of 15

ORIGINALLY CRE ATED A S an alterna- tive for high-risk aortic stenosis surgical patients, TAVR is now appropriate for patients with severe aortic valve stenosis at all surgical risk levels. " W hen ou r pre dom i n a nt pat ient population was in their 80s a nd 90s, they were all high risk, so it wasn't an issue to offer TAVR as an alternative," says James Harvey, MD, MSc, Director of the Structura l Heart Program and interventional cardiologist at WellSpan. "But now it has been approved in low-risk patients, and many of our patients are in their 60s and 70s." The main access approach for TAVR in its inception was the transfemora l approach through a n incision in the leg. W h i le t h is is sti l l t he com mon approach, TAVR can now be performed through an incision in the shoulder, ribs or upper chest. In addition, TAV R is a lso appropri- ate for ma ny patients who have had a prior surgica l aortic va lve replacement with a bioprosthetic surgica l va lve and now have a fa i ling surg ica l biopros- thesis. For these patients, WellSpa n offers bioprosthetic va lve fracturing, a newly developed procedure that uses a high-pressure ba lloon during va lve-in- va lve TAVR to fully expand the failing prosthetic va lve and a llow for complete expa nsion a nd proper function of the new TAVR va lve. WellSpan has an internationally recog- nized TAVR program and is Pennsylvania's top provider of bioprosthetic valve frac- turing. "About 10% of patients who come to WellSpan for TAVR are here because they have a failing prosthetic va lve," says Dr. Harvey. "And 10 to 20% of those have a valve opening of 23 millimeters or smaller. This typically indicates a need for fracturing because otherwise these patients would have worse symptoms and a shorter life." Advances have also help address risks associated with TAVR procedure such as the need for pacemaker implant and the increased risk of stroke within the first year after a TAVR procedure. WellSpan's program has helped its patients fare very well in both areas. WellSpan is a leader when it comes to preventing the need for a pacemaker implant after a TAVR. Nationally, 17% of patients require a pacemaker following TAV R , however at WellSpan, just 3% of our patients fa ll into this category. Given this industry-leading differential, WellSpan and Dr. Harvey have been asked to participate in a 46-site trial to share our best practices. Additiona lly, nationa l averages for the risk of a stroke in the year after a WellSpan Is at the Heart of TAVR Innovation TAVR Approaches TAV R IS PERFORMED in different ways and depends on each person's anatomy. + The transfemoral approach happens through an incision in the leg. + The subclavian approach happens through an incision near the shoulder. + The transapical approach happens through an incision in the chest and between the ribs. + The transaortic approach happens through an incision in the upper chest. During valve-in-valve TAVR, a high pressure balloon is used to fracture the failing prosthetic valve and allow for complete expansion and proper function of the new TAVR valve that is put in place. OVER THE YE ARS SiNCE PHYSiCiANS BEGAN PERFORMiNG TR ANSCATHE TER AORTiC VALVE REPL ACEMENT (TAVR) PROCEDURES, MANY CHANGES AND iNNOVATiONS HAVE iMPROVED THE LiVES OF MANY PATiENTS. 0 8

Articles in this issue

Archives of this issue

view archives of MDNews - Mid Penn - Insights 2020